NCT03722823View on ClinicalTrials.gov

A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 10, 2018

Primary Completion Date

May 7, 2019

Study Completion Date

May 7, 2019

Conditions
Hepatic Impairment
Interventions
DRUG

Tucatinib

300mg oral single dose

Trial Locations (4)

32809

Orlando Clinical Research Center, Orlando

37920

NOCCR Knoxville and Volunteer Research Group, Knoxville

78215

Texas Liver Institute, San Antonio

92780

Orange County Research Center, Tustin

All Listed Sponsors
lead

Seagen Inc.

INDUSTRY

NCT03722823 - A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects | Biotech Hunter | Biotech Hunter